# A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

> **NCT05135715** · PHASE2 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma, Stage II
- HER2-positive
- Advanced Melanoma

## Interventions

- **DRUG:** RC48-ADC

## Key facts

- **NCT ID:** NCT05135715
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-19
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05135715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05135715, "A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05135715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*